Full-Time
Senior Principal Statistical Programmer
Updated on 8/2/2026
Novartis
10,001+ employees
Global pharmaceutical company delivering science-based innovations
Compensation Overview
£49.1k - £91.3k/yr
London, UK
Hybrid
Remote work may be considered; no relocation support is available.
 Biology & Biotech (1) |
|---|
Get referred to Novartis
See people who can refer or advise you
- A Bachelor of Science or Master of Science degree in statistics, computer science, mathematics, data science, life science, or an equivalent relevant field is required.
- Extensive experience and deep expertise in statistical programming languages such as R, SAS, or Python is required, including adopting R packages such as Tidyverse, developing R Shiny applications, using artificial-intelligence-enabled tools, supporting data visualization and Git-based version control, and building reproducible workflows.
- Advanced experience contributing to statistical analysis plans and constructing technical programming specifications is required.
- Advanced knowledge of industry standards, including Clinical Data Interchange Standards Consortium data structures and standard programs, is required.
- A good understanding of regulatory requirements relevant to statistical programming, including Good Clinical Practice and study procedures, is required.
- Experience as a Trial, Lead, or Program Programmer across several studies or project-level activities is required, including coordinating internal or external programmers and transferring knowledge to others.
- The ability to communicate, negotiate, collaborate globally, and influence others is required.
- Lead statistical programming activities as Trial Programmer for one or more trials or as Lead or Program Programmer for a program or indication.
- Coordinate internal and external programmers when needed, make statistical programming decisions, and propose strategies at the study, program, indication, or disease level.
- Act as a functional manager of associates when needed, including providing supervision and guidance on operational and functional expertise and processes.
- Build and maintain effective working relationships with cross-functional teams, summarize and discuss deliverable status and critical programming aspects such as timelines, scope, and resource plans, and represent statistical programming on study- or program-level teams.
- Review electronic case report forms and data structures and ensure program-level standardization for effective pooling and efficient case record tabulation production.
- Comply with company, department, and industry standards and processes; assess and clarify additional programming requirements; and review, develop, and influence programming specifications as part of analysis plans and program-level strategies.
- Provide and implement statistical programming solutions and act as a programming expert in problem-solving activities while enabling knowledge sharing.
- Develop and validate datasets and outputs for clinical study reports, regulatory submissions and interactions, safety reports, publications, post-marketing activities, and exploratory analyses in assigned studies or programs.
- Use Git-based version-control workflows to support collaborative, traceable, and reproducible programming activities.
- Own quality control and inspection readiness for assigned statistical programming deliverables and the accuracy and reliability of statistical analysis results.
- Establish expectations and frameworks for reproducibility, documentation, and code quality across complex workflows, and lead refinement of templates, standards, and governance.
- Maintain advanced knowledge of statistical programming languages and industry requirements such as Clinical Data Interchange Standards Consortium, electronic Common Technical Document, and Define.xml, and act as an expert in advanced analysis, reporting, automation, and enterprise-scale workflow optimization.
- Drive adoption of reusable solutions and modern programming approaches across studies and programs.
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Get referred to Novartis
See people who can refer or advise you
Simplify's Take
What believers are saying
- Preclinical data shows Myricx's NMTi payload achieves complete tumor regression in TOPO-1-resistant models.
- The $1.1B upfront acquisition accelerates Novartis' oncology pipeline with differentiated toxicity profiles.
- Novartis expands treatable solid tumor settings by adding next-generation ADC capabilities to its portfolio.
What critics are saying
- $1.1B upfront for preclinical assets never dosed in humans creates high clinical failure risk within 12–18 months.
- East Hanover, NJ layoffs of 322 employees erode oncology research capacity and accelerate knowledge drain to competitors.
- Stock dropped 2–3% post-deal, signaling investor skepticism over $1.5B oncology bet amid Keytruda patent cliff and Entresto US loss.
What makes Novartis unique
- Novartis internalizes first-in-class NMTi ADC payload platform to overcome TOPO-1 and tubulin resistance.
- The company secures two lead ADC assets targeting B7-H3 and HER2 for solid tumor settings.
- Novartis scales innovative platforms like ADCs, mirroring its successful radioligand therapy manufacturing expansion in Denton, TX.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -4%DKSH Korea expands partnership with Novartis to strengthen hypertension portfolio. Wednesday, July 29, 2026 DKSH Healthcare has expanded its strategic partnership with Novartis in South Korea by adding the hypertension medicines Diovan(R) and Exforge(R) to its prescription drug portfolio. Under the agreement, DKSH Korea will manage local sales, medical affairs and marketing activities for both products, strengthening its presence in the country's prescription medicines market. The collaboration builds on DKSH Korea's existing prescription portfolio, which includes AstraZeneca's hypertension treatment Atacand and haematology and nephrology products from Kyowa Kirin. The agreement further reinforces the company's position in the Korean pharmaceutical market and supports the continued expansion of its healthcare business. Diovan and Exforge are established treatments for hypertension that have been widely used in cardiology departments and primary care settings across South Korea. DKSH Korea plans to use its existing commercial, medical and marketing capabilities to expand the market presence of both medicines. As part of the partnership, the company also intends to recruit additional professionals with expertise in the products and the local pharmaceutical market to support the continued growth of its prescription drug business. The expanded agreement reflects DKSH's strategy of strengthening access to prescription medicines through partnerships with pharmaceutical companies while enhancing its commercial capabilities in South Korea.
HealthCare Institute of New Jersey elects new Board leadership. July 22, 2026, 10:25 am | in Trenton, July 22, 2026 ― The HealthCare Institute of New Jersey (HINJ - www.hinj.org) released the following statement on the election of new officers of its Board of Trustees and the leadership of its Steering Committee, effective July 1. Charles "Chuck" Leitgeb, Deputy Director of State Government Relations, Bayer US, was elected Chair of the Board. Mr. Leitgeb joined Bayer's government relations team in 2014 and is responsible for all state government and legislative activity relevant to Bayer's Pharmaceutical, Consumer Health and Crop Science businesses in the Northeast Region. He also serves as state government relations team lead for Bayer's Radiology business. Prior to joining Bayer, Mr. Leitgeb was Vice President of the Insurance Council of New Jersey - a Trenton-based trade organization representing the property and casualty insurance industry. He also previously served as deputy communications director, and eventually communications director, for the Assembly Republican Office in the New Jersey Legislature. Mr. Leitgeb holds a BA in English/Journalism and a minor in history from Rutgers University. Mr. Leitgeb succeeds Leo Farber, formerly Vice President and Head of U.S. Government Affairs, Novartis. The HINJ Board also elected Adam Brand, Vice President, Government Affairs and Public Policy Corporate Affairs, Otsuka America Pharmaceutical, Inc., to serve as Vice Chair. The Treasurer is Christopher Guiton, Head, Home State Initiatives, Johnson & Johnson. The Board Secretary is Derek Naten, Vice President, Government Affairs & Advocacy, Keenova Therapeutics. HINJ also has announced that Adam Taliaferro, Director, State & Community Engagement, Johnson & Johnson, has been reappointed Chair of the HINJ Steering Committee, and George Coutros, Director, State Government Relations, Sanofi US, has been reappointed Vice Chair. A full listing of the Board is below and can also be found here: https://hinj.org/officers-and-board-of-trustees/ Charles "Chuck" Leitgeb, Chair, Deputy Director of State Government Relations, Bayer US Adam Brand, Vice Chair, Vice President, Government Affairs and Public Policy Corporate Affairs, Otsuka America Pharmaceutical, Inc. Christopher Guiton, Treasurer, Head, Home State Initiatives, Johnson & Johnson Derek Naten, Board Secretary, Vice President, Government Affairs & Advocacy, Keenova Therapeutics Andrew Antrobus, Regional Lead, State Government Affairs, Novo Nordisk, Inc. Domenick Argento, Director, Government Affairs, Merck & Co., Inc. Adam Lotspike, Senior Director, U.S. Government Relations, BD Joseph McGowan, Head, Federal Government Affairs, Novartis Pharmaceuticals Corporation Melissia Whitmarsh, Director, State Government Affairs, Daiichi Sankyo, Inc. About the HealthCare Institute of New Jersey (HINJ) Founded in 1997, the HealthCare Institute of New Jersey (HINJ) is a trade association that serves as the voice for its state's leading research-based biopharmaceutical and medical technology companies. HINJ strives to raise awareness, understanding and public support for the state's life sciences industry, expand patient access to the medical innovations its member companies produce and promote awareness of the life sciences' economic impact in New Jersey. To learn more, please visit www.hinj.org and follow Insider NJ on X, Facebook and LinkedIn. For data on the life sciences' impact on New Jersey's economy, visit its By the Numbers page.
– Multi-target collaboration will leverage Antares’ proprietary discovery engine to generate highly selective small molecule medicines against historically undruggable oncology targets –
Abu Dhabi and Novartis sign strategic Memorandum of Understanding to advance genomics research and healthcare innovation. The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate of Abu Dhabi, and Novartis Middle East FZE today signed a Memorandum of Understanding to explore collaboration in genomics research, scientific capacity building, and advanced therapies, reinforcing their shared commitment to advancing healthcare innovation and improving patient outcomes. The collaboration further strengthens Abu Dhabi's genomics ecosystem by connecting global scientific expertise with one of the world's largest population genomics programmes. The joint efforts in research, capability building and advanced therapies, will support the translation of genomic insights into improved health outcomes for patients in Abu Dhabi and around the world. Through this collaboration, both organisations will build on Abu Dhabi's established strengths in genomics, precision medicine and health innovation, supporting research that is relevant to the UAE population while strengthening local scientific capabilities and advancing access to innovative therapies.The partnership builds on Abu Dhabi's leadership in genomics through the Emirati Genome Program, which has sequenced more than 900,000 genomes to date. These insights are creating new opportunities to advance precision medicine, support population-specific research and accelerate the development of more targeted approaches to prevention, diagnosis and treatment. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health - Abu Dhabi (DoH), said:"Abu Dhabi has established one of the world's most comprehensive population genomics programmes, creating new opportunities to better understand disease, improve prevention and accelerate the development of more personalised approaches to care. This collaboration with Novartis strengthens an ecosystem that already brings together genomics, research, healthcare delivery and innovation within a single connected environment. By combining global scientific expertise with Abu Dhabi's capabilities in genomics and precision medicine, we are accelerating the translation of research into solutions that can improve outcomes for patients and communities." Mohamed Ezz Eldin, Head of Novartis GCC Cluster, added: "We are proud to strengthen our longstanding collaboration with the Department of Health - Abu Dhabi through this strategic Memorandum of Understanding. By combining Abu Dhabi's ambitious vision for healthcare innovation with Novartis' global scientific expertise, we have an opportunity to support advances in genomics research, scientific capability building, and the future of precision medicine. We look forward to exploring initiatives that can contribute to better health outcomes and help address the evolving needs of patients in the UAE." The signing builds on the longstanding relationship between DoH and Novartis across multiple areas, including clinical research, health technology assessment, and policy engagement in innovative treatment areas. The MoU further reflects both organizations' commitment to fostering scientific collaboration, strengthening local capabilities, and supporting innovation that can benefit patients in Abu Dhabi and beyond. The Memorandum of Understanding was signed during a visit by the Department of Health - Abu Dhabi delegation to the Novartis Biomedical Research site in San Diego, held alongside BIO International Convention 2026. The visit included a leadership engagement, site tour, and discussions on future opportunities for collaboration in genomics and biomedical research.
Castle Hill Hospital becomes regional hub for molecular scanning capability in the fight against cancers. A new project could help change regional inequalities in access to advanced diagnostic imaging. A new partnership to fund a physicist at Castle Hill Hospital is making the Hull area a regional hub for advanced imaging diagnostics. Hull University Teaching Hospitals NHS Trust (HUTH) has joined forces with major medicines company Novartis to support diagnostic molecular imaging services which are considered among the best in the UK. Article continues below It coincides with the newly launched Molecular Imaging Research Centre (MIRC) at the Cottingham hospital. The new partnership includes more than two years of funding for a physicist, at Castle Hill Hospital, to support the introduction of a Gallium radiopharmaceutical service and Gallium-Positron Emission Tomography (PET) imaging capability. Gallium radiopharmaceutical is a form of nuclear medicine that uses a gallium isotope attached to a targeting molecule. It is injected and accumulates in certain tissues and tumours, allowing clinicians to detect diseases such as cancer using scans. Article continues below 138205441690 After the initial 27 month funding period, funding will be taken on by HUTH, supported by charity the Daisy Appeal, which has developed and will operate the MIRC facilities. The gallium-68 labelled radio-diagnostic agents are produced using a Gallium generator. And because the isotope has a short half life of just over an hour, on-site production is essential. With the recent acquisition of a Gallium generator, MIRC will soon begin producing these agents for clinical use in Hull. You May Like Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info Gallium-PET imaging is already widely used in the management of nerve and gland (neuro-endocrine) tumours and prostate cancer, while clinical trials across the world are exploring its use in other cancers to support patient selection and monitor response to new therapies. Dr Saleem Azeem, clinical director, Molecular Imaging Research Centre, said: "The introduction of Gallium-PET services in Hull is expected to help address regional inequalities in access to advanced diagnostic imaging. Patients from centres without these facilities will be able to access molecular imaging at Hull, supporting clinical trial participation, therapy readiness and more equitable access to specialist scanning closer to home." Article continues below Did you know you can make Hull Live a preferred source of Hull news in Google, which will mean you get more of our breaking news, exclusives, and must-read stories straight away? Here's more information about what this means and how to do it - you can also do it straight away by clicking here.